Prognostic Significance of the Cribriform Pattern in Prostate Cancer: Clinical Outcomes and Genomic Alterations

Given the diverse clinical progression of prostate cancer (PC) and the evolving significance of histopathological factors in its management, this study aimed to explore the impact of cribriform pattern 4 (CP4) on clinical outcomes in PC patients and examine its molecular characteristics. This retros...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-04, Vol.16 (7), p.1248
Main Authors: Sayan, Mutlay, Tuac, Yetkin, Akgul, Mahmut, Pratt, Grace K, Rowan, Mary D, Akbulut, Dilara, Kucukcolak, Samet, Tjio, Elza, Moningi, Shalini, Leeman, Jonathan E, Orio, Peter F, Nguyen, Paul L, D'Amico, Anthony V, Aktan, Cagdas
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Clinical outcomes
Clinical trials
Development and progression
Estimates
Gene expression
Genes
Genetic aspects
Genomics
Medical prognosis
Metastasis
Mutation
Oncology, Experimental
Pathology
Patient outcomes
Patients
Prostate cancer
Prostatectomy
Risk assessment
Surgery
Tumor cells
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Given the diverse clinical progression of prostate cancer (PC) and the evolving significance of histopathological factors in its management, this study aimed to explore the impact of cribriform pattern 4 (CP4) on clinical outcomes in PC patients and examine its molecular characteristics. This retrospective study analyzed data from The Cancer Genome Atlas (TCGA) database and included PC patients who underwent radical prostatectomy (RP) and had pathology slides available for the assessment of CP4. A multivariable competing risk regression analysis was used to assess the association between CP4 and progression-free survival (PFS) while adjusting for established PC prognostic factors. The frequency of genomic alterations was compared between patients with and without CP4 using the Fisher's exact test. Among the 394 patients analyzed, 129 (32.74%) had CP4. After a median follow-up of 40.50 months (IQR: 23.90, 65.60), the presence of CP4 was significantly associated with lower PFS (AHR, 1.84; 95% CI, 1.08 to 3.114; = 0.023) after adjusting for covariates. Seven hub genes-KRT13, KRT5, KRT15, COL17A1, KRT14, KRT16, and TP63-had significantly lower mRNA expression levels in patients with CP4 compared to those without. PC patients with CP4 have distinct genomic alterations and are at a high risk of disease progression following RP. Therefore, these patients may benefit from additional post-RP treatments and should be the subject of a prospective randomized clinical trial.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16071248